Select Page

South Delhi Pharma, New Delhi, India

AVSOLA (infliximab-axxq) for injection, for intravenous use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

AVSOLA is a prescription medicine. AVSOLA is used to treat arthritis, CD, UC and skin disease.
INDICATIONS AND USAGE
AVSOLA is a tumor necrosis factor (TNF) blocker indicated for:
Crohn’s Disease, Pediatric Crohn’s Disease, Ulcerative Colitis, Pediatric Ulcerative Colitis, Rheumatoid Arthritis in combination with methotrexate, Ankylosing Spondylitis, Psoriatic Arthritis.
DOSAGE FORMS & STRENGTHS
For injection: 100 mg of lyophilized infliximab-axxq in a 20 mL single-dose vial for intravenous infusion.
Manufactured By: Amgen Medical Information
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “AAVSOLA (infliximab-axxq) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

6 + 8 =

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

Infliximab was approved for medical use in the United States in 1998, and in the European Union in August 1999. Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019).

Reviews

There are no reviews yet.

Be the first to review “AVSOLA (infliximab-axxq) for injection, for intravenous use”

Your email address will not be published.